$TWST

WERNER ROBERT F. sold $14K of TWST

WERNER ROBERT F. (Chief Accounting Officer) sold 167 shares of Twist Bioscience Corp (TWST) at $85.32 on 2026-08-03.

Original reporting
SEC EDGAR · WERNER ROBERT F.
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new guidance, contracts, litigation, or operational developments.

02

Market read

Traders may note insider selling, but the transaction size and lack of company-specific news make it low signal.

03

What to watch

Insider sales can be driven by taxes, diversification, or pre-existing personal liquidity needs; without additional context, this should not be treated as a directional fundamental view.

Relevance 3/10Novelty 2/10Timing: filed Aug 5, transaction dated Aug 3

Background

The article is a SEC Form 4 insider transaction disclosure for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience disclosed a Form 4 showing Chief Accounting Officer Robert Werner sold 167 shares at $85.3212 on Aug 3.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and should fade quickly.

Evidence & confidence

Form 4 insider sales are common and this transaction is modest ($14.2k). The filing provides no new company-specific operational or financial information.

Market effects

No clear sector read-through from a small, routine insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as discretionary selling, but the dollar size is too small to imply a strong negative signal.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale by its Chief Accounting Officer.

  • Robert F. Werner

    Chief Accounting Officer who sold 167 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.